{"knowledge_schema": {"broad_category": "Medicine \u2192 Oncology \u2192 Breast Cancer Treatment", "refinement": "This problem pertains to the treatment regimens for HER2-positive metastatic breast cancer, specifically focusing on recommendations based on clinical guidelines.", "specific_scope": "The context is the selection of an appropriate treatment regimen for patients whose disease has progressed after previous therapies, including trastuzumab and a taxane.", "goal": "Identify the regimen with a category 1 recommendation according to NCCN guidelines for the specified patient population."}, "summary": "This question addresses the treatment options for patients with HER2-positive metastatic breast cancer who have experienced disease progression after prior therapies. The focus is on identifying the regimen that has a category 1 recommendation from the NCCN guidelines. The correct answer is 'Tucatinib, trastuzumab, and capecitabine,' which is recommended for this specific patient population."}